Proof of Concept Trial of Vamorolone in Pediatric Ulcerative Colitis
Status:
Withdrawn
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase I/II, multi-center, open-label proof-of-concept study of vamorolone. Twenty
participants with a flare of mild or moderately active Ulcerative Colitis (defined as a
Pediatric Ulcerative Colitis Activity Index [PUCAI] 10-60) will be enrolled and receive
vamorolone 6 mg/kg/day orally once daily for 8 weeks.